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Cataract is an increasing opalescence of the ocular lens,
ultimately leading to decrease of eyesight. The opalescence of the
lens can be assessed by asking the patient what he/she yet
perceives, or to assess the lens with objective measurements. A
number of methods aÍe compared in this thesis: visual acuity,
contrast sensitivity, intraocular straylight, Iens autofluorescence
and transmission. Additionally these methods were used in a
clinical trial for the efficacy of a drug, Bendazac-lysine, in the
prevention of cataracts formation. The control group of the
clinical trial was used to evaluate the lens measurements.
In chapter 1 a general survey is presented on the nowadays
knowledge on the origin of cataract. The crystalline lens becomes
opalescent when the normal lens fibre- and protein structures are
changed. Cause and effect of these changes are discussed.
Chapter 2 gives a survey of the various assessment methods
to evaluate the cataractous lens changes, as reported in the
literature.
Chapter -J contains a description of the methods we used in
our study. In case of intraocular straylight measurement, lens
auto-fluorescence and transmission, additionally results of normal
values and reproducibility analysis are presented.
Chapter 4 describes the results of measurements in 43
patients from the drug trial. These preliminary results demonstrate
that patients can read 3 to 4 optotypes more on the chart
containing letters of the alphabet than on the chart containing the
Landolt-C. The contrast test demonstrates a decreased conrrast
sensitivity in all spatial frequencies, compared with normals. The
intraocular straylight is increased. Autofluorescence of the lens
also is increased in comparison to normals and a significant
correlation between autofluorescence and transmission was found.
These results are in agreement with our expectations, so we
conclude these methods to be adequate to assess cataractous lens
changes.
In chapter 5 further analysis is presented on the differences
of results of visual acuity, measured with the two charts. The two
charts have equivalent reproducibility, so they are both equally
reliable. The differences that where found was not dependent of
























Chapter ó. In our drug trial, disability glare caused by the
cataractous lens was assessed by measuring the intraocular
straylight. The backward scatter of light can equally be used as an
evaluation of straylight. In general this is performed by use of
sophisticated apparatus. We have used an automatic system to
analyze the slitlamp image of the lens, in order to measure the
backward scatter. This method proved to have a good
reproducibility.
Contrast sensitivity is usually determined by presenting
targets containing sinusoidal gratings with decreasing contrast.
The lowest perceived contrast of one wave size determines
contrast sensitivity at that spatial frequency. It is described in the
literature that an adequate number of sinus waves should be
presented in order to perform the test properly. According to
these data, the chart we used in our trial contains insufficient
waves in case of the low frequencies. We investigated this
finding, and discussed the results in chapter 7. Contrast
sensitivity indeed increases when a larger number of sinus waves
are presented. This means that with the chart we used, in some of
the frequencies an erroneous contrast sensitivity is measured. This
fact is of no consequence for the outcome of the trial.
Chapter 8. In healthy subjects as well as in cataract
patients, a strong correlation is found between lens auto-
fluorescence and age. It seems that in case of nuclear cataracts the
fluorescence is stronger than in cortical cataracts. Additionally in
the nuclear cataracts the one-year increase is stronger. We
showed that this one-year increase is more related with the
fluorescence at baseline measurement han with age or cataract
type.
Visual acuity, contrast sensitivity and intraocular straylight
are theoretically correlated. In chapter 9 a direct correlation
between visual acuity and contrast sensitivity is described, such a
correlation with intraocular straylight was not found. However,
when changes of these measurements in t ime are correlated, in six
months to one year correlations are significant. This demonstrates
that although no direct correlation of visual acuity and contrast
sensitivity with intraocular straylight are found, the developments
in time are correlated.
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In the last decades various drugs were developed that could
have a beneficial effect on the progression of cataract. One of
these drugs is Bendazac. In a number of drug trials this effect was
demonstrated. A survey of the literature on Bendazac is in
chapter 10.
Chapter I l. A drug trial is usually designed to determine
the efficacy of a drug on symptoms or disease. In order to avoid
as much disturbing influences as possible, uncompromising
inclusion criteria are necessary. Because of the difficulty to
estimate the number of excluded patients, one usually overlooks
the dimension of this problem. Initially we also underestimated
the recruitment period. The enrolment of patients in the
Bendazac-lysine trial is discussed in detail.
Chapter 12. A total of 50 cataract patients participated in
the trial. We did not find any significant differences between the
patient treated with Bendazac and the placebo group. In both
visual acuity and contrast sensitivity measurements there are some
indications in favour of Bendazac-lysine. Here more patients
showed improvement and less patients worsening compared with
the controls. This different however was statistically not
significant.
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